Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

NCT ID: NCT01690598

Last Updated: 2015-06-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2015-02-28

Brief Summary

The purpose of this study is to investigate the effect of combined topotecan and veliparib (ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or unknown BRCA mutation status.

Conditions

Ovarian Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Veliparib and Topotecan

Group Type: EXPERIMENTAL

Veliparib

Intervention Type: DRUG

Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.

Topotecan

Intervention Type: DRUG

2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².

Interventions

Veliparib

Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.

Intervention Type: DRUG

Topotecan

2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.

2. Verified progression by either RECIST criteria and/or GCIG CA125 criteria after previous first line chemotherapy or progression after later lines of cytotoxic treatment.

3. Platinum resistance or partially platinum sensitive disease

• Relapsed within six months of prior first line/later lines of platinum-based therapy or
• Relapsed within six-twelve months of prior first line/later lines of platinum-based therapy

4. Age ≥ 18 years.

5. Performance status 0-2.

6. Measurable disease by RECIST 1.1 or CA125 GCIG criteria

7. Adequate bone marrow function, liver function, renal function and coagulation parameters (within 7 days prior to enrollment):

• WBC ≥ 3.0 x 10^9/l or neutrophils (ANC) ≥ 1.5 x 10^9/l
• Platelet count ≥ 100 x 109/l
• Hemoglobin ≥ 9.7 g/dl (6 mmol/L)
• Serum bilirubin ≤ 1.5 x ULN
• Serum transaminases ≤ 2.5 x ULN
• Serum creatinine ≤ 1.5 x ULN

8. Written informed consent.

9. Tissue available for BRCAness analysis/BRCA mutation analysis.

Exclusion Criteria

1. Prior treatment with a PARP inhibitor.

2. Patients with BRCA1/2 germline mutation.

3. Platinum-refractory disease (disease that progressed or was stable during prior platinum therapy)

4. Patients who have received (or are planning to receive) treatment with any other investigational agent, or who have participated in another clinical trial within 28 days prior to entering this trial.

5. Pregnant or breast-feeding. For fertile women a negative pregnancy test at screening is mandatory.

6. Fertile patients not willing to use acceptable and safe methods of contraception during and for 6 months after treatment

7. Other present or previous malignancy except curatively treated cervical cancer stage I, non-melanotic skin cancer or other cancer with minimal risk of relapse. Previous breast cancer is allowed, if disease free follow-up at least five years prior to enrollment.

8. CNS metastasis.

9. History of any chronic medical or psychiatric condition or laboratory abnormality, which is not medically controlled or in the opinion of the Investigator may increase the risks associated with study drug administration (e.g. diabetes, cardiac diseases, hypertension, renal or liver disease).

10. Allergy to the ingredients of the study medication.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: collaborator

Vejle Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anders Jakobsen, MD, DMSc

Role: STUDY_CHAIR

Vejle Hospital

Hanne Kanstrup, MD

Role: PRINCIPAL_INVESTIGATOR

Vejle Hospital

Locations

Department of Oncology, Vejle Hospital

Vejle, , Denmark

Countries

Denmark

References

Hjortkjaer M, Kanstrup H, Jakobsen A, Steffensen KD. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27. No abstract available.

Reference Type: DERIVED

PMID: 30104007 (View on PubMed)

Other Identifiers

VeTo

Identifier Type: -

Identifier Source: org_study_id